

Recombinant Human CLDN18.1 (N-8His)

Catalog No: CR54

| | |
|-----------------------------------|---|
| Description | Recombinant Human CLDN18.1 is produced by our E.coli expression system and the target gene encoding Asp28-Leu76 is expressed with a 8His tag at the N-terminus. |
| Expression System | E.coli |
| Alternative name | Claudin-18; CLDN18 |
| Accession No. | P56856 |
| Predicted Molecular Weight | 19.8kDa |
| Apparent Molecular Weight | 18kDa, reducing conditions. |
| Quality Control | Purity: greater than 95% as determined by reducing SDS-PAGE. Endotoxin: less than 0.1 ng/μg (1 EU/μg) as determined by LAL test. |
| Formulation | Supplied as a 0.2 μm filtered solution of 25mM Tris-HCl, 25mM NaCl, 10% Glycerol, pH 8.0. |
| Shipping | The product is shipped on dry ice pack. Upon receipt, store it immediately at the temperature listed below. |
| Storage | Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles. |
| Background | Claudin-18(CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG. |

SDS-PAGE

